Proteomics in Inherited Metabolic Disorders
Abstract
:1. Introduction
2. Proteomic Strategies
2.1. Qualitative and Quantitative Proteomics
2.1.1. Qualitative Proteomics
2.1.2. Quantitative Proteomics Approach
2.1.3. Targeted Proteomics
2.1.4. Affinity-Based (Probes and Antibodies) Proteomics Approaches [35,36,37,38]
3. Proteomics for the Study of IMD
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Marwaha, S.; Knowles, J.W.; Ashley, E.A. A guide for the diagnosis of rare and undiagnosed disease: Beyond the exome. Genome Med. 2022, 14, 23. [Google Scholar] [CrossRef] [PubMed]
- Stenton, S.L.; Kremer, L.S.; Kopajtich, R.; Ludwig, C.; Prokisch, H. The diagnosis of inborn errors of metabolism by an integrative “multi-omics” approach: A perspective encompassing genomics, transcriptomics, and proteomics. J. Inherit. Metab. Dis. 2020, 43, 25–35. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, C.R.; Rahman, S.; Keller, M.; Zschocke, J.; Abdenur, J.; Ali, H.; Artuch, R.; Ballabio, A.; Barshop, B.; Baumgartner, M.; et al. An international classification of inherited metabolic disorders (ICIMD). J. Inherit. Metab. Dis. 2021, 44, 164–177. [Google Scholar] [CrossRef] [PubMed]
- Mussap, M.; Zaffanello, M.; Fanos, V. Metabolomics: A challenge for detecting and monitoring inborn errors of metabolism. Ann. Transl. Med. 2018, 6, 338. [Google Scholar] [CrossRef]
- Ghosh, A.; Schlecht, H.; Heptinstall, L.E.; Bassett, J.K.; Cartwright, E.; Bhaskar, S.S.; Urquhart, J.; Broomfield, A.; Morris, A.A.; Jameson, E.; et al. Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing. Arch. Dis. Child. 2017, 102, 1019–1029. [Google Scholar] [CrossRef] [Green Version]
- Ortigoza-Escobar, J.D. A Proposed Diagnostic Algorithm for Inborn Errors of Metabolism Presenting with Movements Disorders. Front. Neurol. 2020, 11, 1353. [Google Scholar] [CrossRef]
- Ismail, I.T.; Showalter, M.R.; Fiehn, O. Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics. Metabolites 2019, 9, 242. [Google Scholar] [CrossRef] [Green Version]
- Velez, G.; Tang, P.H.; Cabral, T.; Cho, G.Y.; Machlab, D.A.; Tsang, S.H.; Bassuk, A.G.; Mahajan, V.B. Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease. Transl. Vis. Sci. Technol. 2018, 7, 12. [Google Scholar] [CrossRef] [Green Version]
- Ferreira, C.R.; van Karnebeek, C.D.M.; Vockley, J.; Blau, N. A proposed nosology of inborn errors of metabolism. Genet. Med. 2018, 21, 102–106. [Google Scholar] [CrossRef] [Green Version]
- Leonard, J.V.; Morris, A.A.M. Inborn errors of metabolism around time of birth. Lancet 2000, 356, 583–587. [Google Scholar] [CrossRef]
- Dayon, L.; Cominetti, O.; Affolter, M. Proteomics of human biological fluids for biomarker discoveries: Technical advances and recent applications. Expert Rev. Proteom. 2022, 19, 131–151. [Google Scholar] [CrossRef] [PubMed]
- Geyer, P.E.; Holdt, L.M.; Teupser, D.; Mann, M. Revisiting biomarker discovery by plasma proteomics. Mol. Syst. Biol. 2017, 13, 942. [Google Scholar] [CrossRef] [PubMed]
- Lone, S.N.; Nisar, S.; Masoodi, T.; Singh, M.; Rizwan, A.; Hashem, S.; El-Rifai, W.; Bedognetti, D.; Batra, S.K.; Haris, M.; et al. Liquid biopsy: A step closer to transform diagnosis, prognosis and future of cancer treatments. Mol. Cancer 2022, 21, 79. [Google Scholar] [CrossRef]
- Verrills, N.M. Clinical proteomics: Present and future prospects. Clin. Biochem. Rev. 2006, 27, 99–116. [Google Scholar]
- Vlahou, A. Implementation of Clinical Proteomics: A Step Closer to Personalized Medicine? Proteom. Clin. Appl. 2019, 13, 1800088. [Google Scholar] [CrossRef]
- Dupree, E.J.; Jayathirtha, M.; Yorkey, H.; Mihasan, M.; Petre, B.A.; Darie, C.C. A Critical Review of Bottom-Up Proteomics: The Good, the Bad, and the Future of This Field. Proteomes 2020, 8, 14. [Google Scholar] [CrossRef] [PubMed]
- Meyer, J.G. Qualitative and Quantitative Shotgun Proteomics Data Analysis from Data-Dependent Acquisition Mass Spectrometry. Methods Mol. Biol. 2021, 2259, 297. [Google Scholar] [CrossRef]
- Hou, T.Y.; Chiang-Ni, C.; Teng, S.H. Current status of MALDI-TOF mass spectrometry in clinical microbiology. J. Food Drug Anal. 2019, 27, 404–414. [Google Scholar] [CrossRef]
- Al-Amrani, S.; Al-Jabri, Z.; Al-Zaabi, A.; Alshekaili, J.; Al-Khabori, M. Proteomics: Concepts and applications in human medicine. World J. Biol. Chem. 2021, 12, 57–69. [Google Scholar] [CrossRef]
- Issaq, H.J.; Veenstra, T.D. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): Advances and perspectives. BioTechniques 2008, 44, 697–700. [Google Scholar] [CrossRef] [Green Version]
- Griffiths, J. A brief history of mass spectrometry. Anal. Chem. 2008, 80, 5678–5683. [Google Scholar] [CrossRef] [PubMed]
- Siuzdak, G. An Introduction to Mass Spectrometry Ionization: An Excerpt from The Expanding Role of Mass Spectrometry in Biotechnology, 2nd ed.; MCC Press: San Diego, 2005. JALA J. Assoc. Lab. Autom. 2016, 9, 50–63. [Google Scholar] [CrossRef] [Green Version]
- Nadler, W.M.; Waidelich, D.; Kerner, A.; Hanke, S.; Berg, R.; Trumpp, A.; Rösli, C. MALDI versus ESI: The Impact of the Ion Source on Peptide Identification. J. Proteome Res. 2017, 16, 1207–1215. [Google Scholar] [CrossRef]
- Cupp-Sutton, K.A.; Wu, S. High-throughput quantitative top-down proteomics. Mol. Omics 2020, 16, 91. [Google Scholar] [CrossRef] [PubMed]
- Rozanova, S.; Barkovits, K.; Nikolov, M.; Schmidt, C.; Urlaub, H.; Marcus, K. Quantitative Mass Spectrometry-Based Proteomics: An Overview. Methods Mol. Biol. 2021, 2228, 85–116. [Google Scholar] [CrossRef] [PubMed]
- Gillet, L.C.; Navarro, P.; Tate, S.; Röst, H.; Selevsek, N.; Reiter, L.; Bonner, R.; Aebersold, R. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis. Mol. Cell. Proteom. MCP 2012, 11. [Google Scholar] [CrossRef] [Green Version]
- Ludwig, C.; Gillet, L.; Rosenberger, G.; Amon, S.; Collins, B.C.; Aebersold, R. Data-independent acquisition-based SWATH-MS for quantitative proteomics: A tutorial. Mol. Syst. Biol. 2018, 14, e8126. [Google Scholar] [CrossRef]
- Wang, Q.; Zhang, M.; Tomita, T.; Vogelstein, J.T.; Zhou, S.; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B. Selected reaction monitoring approach for validating peptide biomarkers. Proc. Natl. Acad. Sci. USA 2017, 114, 13519–13524. [Google Scholar] [CrossRef] [Green Version]
- Sobsey, C.A.; Ibrahim, S.; Richard, V.R.; Gaspar, V.; Mitsa, G.; Lacasse, V.; Zahedi, R.P.; Batist, G.; Borchers, C.H. Targeted and Untargeted Proteomics Approaches in Biomarker Development. Proteomics 2020, 20, 1900029. [Google Scholar] [CrossRef]
- Mermelekas, G.; Vlahou, A.; Zoidakis, J. SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine. Expert Rev. Mol. Diagn. 2015, 15, 1441–1454. [Google Scholar] [CrossRef]
- Manes, N.P.; Mann, J.M.; Nita-Lazar, A. Selected reaction monitoring mass spectrometry for absolute protein quantification. J. Vis. Exp. 2015, 2015, e52959. [Google Scholar] [CrossRef] [PubMed]
- Ahsan, N.; Rao, R.S.P.; Gruppuso, P.A.; Ramratnam, B.; Salomon, A.R. Targeted proteomics: Current status and future perspectives for quantification of food allergens. J. Proteom. 2016, 143, 15–23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rauniyar, N. Parallel reaction monitoring: A targeted experiment performed using high resolution and high mass accuracy mass spectrometry. Int. J. Mol. Sci. 2015, 16, 28566–28581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Padula, M.; Berry, I.; O′Rourke, M.; Raymond, B.; Santos, J.; Djordjevic, S.P. A Comprehensive Guide for Performing Sample Preparation and Top-Down Protein Analysis. Proteomes 2017, 5, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fonović, M.; Bogyo, M. Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev. Proteom. 2008, 5, 721–730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ayoglu, B.; Chaouch, A.; Lochmüller, H.; Politano, L.; Bertini, E.; Spitali, P.; Hiller, M.; Niks, E.H.; Gualandi, F.; Pontén, F.; et al. Affinity proteomics within rare diseases: A BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Mol. Med. 2014, 6, 918–936. [Google Scholar] [CrossRef] [PubMed]
- Olsson, N.; Wingren, C.; Mattsson, M.; James, P.; O’Connell, D.; Nilsson, F.; Cahill, D.J.; Borrebaeck, C.A.K. Proteomic analysis and discovery using affinity proteomics and mass spectrometry. Mol. Cell. Proteom. 2011, 10, M110.003962. [Google Scholar] [CrossRef] [Green Version]
- Wik, L.; Nordberg, N.; Broberg, J.; Björkesten, J.; Assarsson, E.; Henriksson, S.; Grundberg, I.; Pettersson, E.; Westerberg, C.; Liljeroth, E.; et al. Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide Analysis. Mol. Cell. Proteom. 2021, 20, 100168. [Google Scholar] [CrossRef]
- Chen, X.; Wang, Y.; Ma, N.; Tian, J.; Shao, Y.; Zhu, B.; Wong, Y.K.; Liang, Z.; Zou, C.; Wang, J. Target identification of natural medicine with chemical proteomics approach: Probe synthesis, target fishing and protein identification. Signal Transduct. Target. Ther. 2020, 5, 72. [Google Scholar] [CrossRef]
- Stefely, J.A.; Kwiecien, N.W.; Freiberger, E.C.; Richards, A.L.; Jochem, A.; Rush, M.J.P.; Ulbrich, A.; Robinson, K.P.; Hutchins, P.D.; Veling, M.T.; et al. Mitochondrial protein functions elucidated by multi-omic mass spectrometry profiling. Nat. Biotechnol. 2016, 34, 1191–1197. [Google Scholar] [CrossRef] [Green Version]
- Zelezniak, A.; Vowinckel, J.; Capuano, F.; Messner, C.B.; Demichev, V.; Polowsky, N.; Mülleder, M.; Kamrad, S.; Klaus, B.; Keller, M.A.; et al. Machine Learning Predicts the Yeast Metabolome from the Quantitative Proteome of Kinase Knockouts. Cell Syst. 2018, 7, 269–283.e6. [Google Scholar] [CrossRef]
- Matsuda, F.; Kinoshita, S.; Nishino, S.; Tomita, A.; Shimizu, H. Targeted proteome analysis of single-gene deletion strains of Saccharomyces cerevisiae lacking enzymes in the central carbon metabolism. PLoS ONE 2017, 12, e0172742. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grabowski, P.; Hesse, S.; Hollizeck, S.; Rohlfs, M.; Behrends, U.; Sherkat, R.; Tamary, H.; Ünal, E.; Somech, R.; Patiroǧlu, T.; et al. Proteome Analysis of Human Neutrophil Granulocytes from Patients with Monogenic Disease Using Data-independent Acquisition. Mol. Cell. Proteom. MCP 2019, 18, 760–772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aslam, B.; Basit, M.; Nisar, M.A.; Khurshid, M.; Rasool, M.H. Proteomics: Technologies and their applications. J. Chromatogr. Sci. 2017, 55, 182–196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Richard, E.; Gamez, A.; Ruiz-Sala, P.; Perez, B.; Desviat, L.; Ugarte, M. Proteomics as Applied to Inherited Metabolic Diseases. Curr. Proteom. 2009, 6, 140–153. [Google Scholar] [CrossRef]
- Frésard, L.; Smail, C.; Ferraro, N.M.; Teran, N.A.; Li, X.; Smith, K.S.; Bonner, D.; Kernohan, K.D.; Marwaha, S.; Zappala, Z.; et al. Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nat. Med. 2019, 25, 911–919. [Google Scholar] [CrossRef]
- Lee, H.; Huang, A.Y.; Wang, L.k.; Yoon, A.J.; Renteria, G.; Eskin, A.; Signer, R.H.; Dorrani, N.; Nieves-Rodriguez, S.; Wan, J.; et al. Diagnostic utility of transcriptome sequencing for rare Mendelian diseases. Genet. Med. 2020, 22, 490–499. [Google Scholar] [CrossRef]
- Sirrs, S.; van Karnebeek, C.D.M.; Peng, X.; Shyr, C.; Tarailo-Graovac, M.; Mandal, R.; Testa, D.; Dubin, D.; Carbonetti, G.; Glynn, S.E.; et al. Defects in fatty acid amide hydrolase 2 in a male with neurologic and psychiatric symptoms. Orphanet J. Rare Dis. 2015, 10, 38. [Google Scholar] [CrossRef] [Green Version]
- Splinter, K.; Adams, D.R.; Bacino, C.A.; Bellen, H.J.; Bernstein, J.A.; Cheatle-Jarvela, A.M.; Eng, C.M.; Esteves, C.; Gahl, W.A.; Hamid, R.; et al. Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. N. Engl. J. Med. 2018, 379, 2131–2139. [Google Scholar] [CrossRef]
- Crowther, L.M.; Poms, M.; Plecko, B. Multiomics tools for the diagnosis and treatment of rare neurological disease. J. Inherit. Metab. Dis. 2018, 41, 425–434. [Google Scholar] [CrossRef] [Green Version]
- Ulfenborg, B. Vertical and horizontal integration of multi-omics data with miodin. BMC Bioinform. 2019, 20, 649. [Google Scholar] [CrossRef] [PubMed]
- Maceachern, S.J.; Forkert, N.D. Machine learning for precision medicine. Genome 2021, 64, 416–425. [Google Scholar] [CrossRef] [PubMed]
- Picard, M.; Scott-Boyer, M.P.; Bodein, A.; Périn, O.; Droit, A. Integration strategies of multi-omics data for machine learning analysis. Comput. Struct. Biotechnol. J. 2021, 19, 3735–3746. [Google Scholar] [CrossRef] [PubMed]
- Reel, P.S.; Reel, S.; Pearson, E.; Trucco, E.; Jefferson, E. Using machine learning approaches for multi-omics data analysis: A review. Biotechnol. Adv. 2021, 49, 107739. [Google Scholar] [CrossRef] [PubMed]
- Almeida, L.S.; Pereira, C.; Aanicai, R.; Schröder, S.; Bochinski, T.; Kaune, A.; Urzi, A.; Spohr, T.C.L.S.; Viceconte, N.; Oppermann, S.; et al. An integrated multiomic approach as an excellent tool for the diagnosis of metabolic diseases: Our first 3720 patients. Eur. J. Hum. Genet. 2022, 30, 1029–1035. [Google Scholar] [CrossRef] [PubMed]
- Clayton, P.T. Applications of mass spectrometry in the study of inborn errors of metabolism. J. Inherit. Metab. Dis. 2001, 24, 139–150. [Google Scholar] [CrossRef] [PubMed]
- Schäfer, J.A.; Bozkurt, S.; Michaelis, J.B.; Klann, K.; Münch, C. Global mitochondrial protein import proteomics reveal distinct regulation by translation and translocation machinery. Mol. Cell 2022, 82, 435–446. [Google Scholar] [CrossRef]
- Zhou, M.T.; Qin, Y.; Li, M.; Chen, C.; Chen, X.; Shu, H.B.; Guo, L. Quantitative Proteomics Reveals the Roles of Peroxisome-associated Proteins in Antiviral Innate Immune Responses. Mol. Cell. Proteom. MCP 2015, 14, 2535. [Google Scholar] [CrossRef] [Green Version]
- Schröder, B.A.; Wrocklage, C.; Hasilik, A.; Saftig, P. The proteome of lysosomes. Proteomics 2010, 10, 4053–4076. [Google Scholar] [CrossRef]
- Caterino, M.; Chandler, R.J.; Sloan, J.L.; Dorko, K.; Cusmano-Ozog, K.; Ingenito, L.; Strom, S.C.; Imperlini, E.; Scolamiero, E.; Venditti, C.P.; et al. The proteome of methylmalonic acidemia (MMA): Elucidation of altered pathways in patient livers. Mol. Biosyst. 2016, 12, 566. [Google Scholar] [CrossRef] [Green Version]
- Simonetta, I.; Tuttolomondo, A.; Daidone, M.; Pinto, A. Biomarkers in Anderson–Fabry disease. Int. J. Mol. Sci. 2020, 21, 8080. [Google Scholar] [CrossRef]
- Tebani, A.; Mauhin, W.; Abily-Donval, L.; Lesueur, C.; Berger, M.G.; Nadjar, Y.; Berger, J.; Benveniste, O.; Lamari, F.; Laforêt, P.; et al. A proteomics-based analysis reveals predictive biological patterns in Fabry disease. J. Clin. Med. 2020, 9, 1325. [Google Scholar] [CrossRef] [PubMed]
- Rossi, F.; L’Imperio, V.; Marti, H.P.; Svarstad, E.; Smith, A.; Bolognesi, M.M.; Magni, F.; Pagni, F.; Pieruzzi, F. Proteomics for the study of new biomarkers in Fabry disease: State of the art. Mol. Genet. Metab. 2021, 132, 86–93. [Google Scholar] [CrossRef] [PubMed]
- Matafora, V.; Cuccurullo, M.; Beneduci, A.; Petrazzuolo, O.; Simeone, A.; Anastasio, P.; Mignani, R.; Feriozzi, S.; Pisani, A.; Comotti, C.; et al. Early markers of Fabry disease revealed by proteomics. Mol. BioSystems 2015, 11, 1543–1551. [Google Scholar] [CrossRef] [PubMed]
- Manwaring, V.; Heywood, W.E.; Clayton, R.; Lachmann, R.H.; Keutzer, J.; Hindmarsh, P.; Winchester, B.; Heales, S.; Mills, K. The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: Evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients. J. Proteome Res. 2013, 12, 2013–2021. [Google Scholar] [CrossRef]
- Hollander, Z.; Dai, D.L.Y.; Putko, B.N.; Yogasundaram, H.; Wilson-Mcmanus, J.E.; Thompson, R.B.; Khan, A.; West, M.L.; McManus, B.M.; Oudit, G.Y. Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease. Eur. J. Heart Fail. 2015, 17, 291–300. [Google Scholar] [CrossRef] [Green Version]
- Doykov, I.D.; Heywood, W.E.; Nikolaenko, V.; Śpiewak, J.; Hällqvist, J.; Clayton, P.T.; Mills, P.; Warnock, D.G.; Nowak, A.; Mills, K. Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease. J. Med. Genet. 2020, 57, 38–47. [Google Scholar] [CrossRef]
- Pawliński, Ł.; Tobór, E.; Suski, M.; Biela, M.; Polus, A.; Kieć-Wilk, B. Proteomic biomarkers in Gaucher disease. J. Clin. Pathol. 2021, 74, 25–29. [Google Scholar] [CrossRef]
- Baldo, G.; Lorenzini, D.M.; Santos, D.S.; Mayer, F.Q.; Vitry, S.; Bigou, S.; Heard, J.M.; Matte, U.; Giugliani, R. Shotgun proteomics reveals possible mechanisms for cognitive impairment in Mucopolysaccharidosis I mice. Mol. Genet. Metab. 2015, 114, 138–145. [Google Scholar] [CrossRef]
- Heywood, W.E.; Camuzeaux, S.; Doykov, I.; Patel, N.; Preece, R.L.; Footitt, E.; Cleary, M.; Clayton, P.; Grunewald, S.; Abulhoul, L.; et al. Proteomic Discovery and Development of a Multiplexed Targeted MRM-LC-MS/MS Assay for Urine Biomarkers of Extracellular Matrix Disruption in Mucopolysaccharidoses I, II, and VI. Anal. Chem. 2015, 87, 12238–12244. [Google Scholar] [CrossRef]
- Van den Broek, B.T.A.; Lindemans, C.A.; Boelens, J.J.; Delemarre, E.M.; Drylewicz, J.; Verhoeven-Duif, N.; van Hasselt, P.M.; Nierkens, S. Long-Term effect of hematopoietic cell transplantation on systemic inflammation in patients with mucopolysaccharidoses. Blood Adv. 2021, 5, 3092–3101. [Google Scholar] [CrossRef]
- Zhang, T.; Duong, P.; Dayuha, R.; Collins, C.J.; Beckman, E.; Thies, J.; Chang, I.; Lam, C.; Sun, A.; Scott, A.I.; et al. A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Mucopolysaccharidosis type I. Mol. Genet. Metab. 2022, 136, 296–305. [Google Scholar] [CrossRef] [PubMed]
- De Pasquale, V.; Costanzo, M.; Siciliano, R.A.; Mazzeo, M.F.; Pistorio, V.; Bianchi, L.; Marchese, E.; Ruoppolo, M.; Pavone, L.M.; Caterino, M. Proteomic analysis of mucopolysaccharidosis IIIB mouse brain. Biomolecules 2020, 10, 355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Víctor Álvarez, J.; Bravo, S.B.; García-Vence, M.; de Castro, M.J.; Luzardo, A.; Colón, C.; Tomatsu, S.; Otero-Espinar, F.J.; Couce, M.L. Proteomic Analysis in Morquio A Cells Treated with Immobilized Enzymatic Replacement Therapy on Nanostructured Lipid Systems. Int. J. Mol. Sci. 2019, 20, 4610. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Álvarez, V.J.; Bravo, S.B.; Chantada-Vazquez, M.P.; Colón, C.; de Castro, M.J.; Morales, M.; Vitoria, I.; Tomatsu, S.; Otero-Espinar, F.J.; Couce, M.L. Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA. Int. J. Mol. Sci. 2020, 22, 226. [Google Scholar] [CrossRef]
- Álvarez, J.V.; Bravo, S.B.; Chantada-Vázquez, M.P.; Barbosa-Gouveia, S.; Colón, C.; López-Suarez, O.; Tomatsu, S.; Otero-Espinar, F.J.; Couce, M.L. Plasma Proteomic Analysis in Morquio A Disease. Int. J. Mol. Sci. 2021, 22, 6165. [Google Scholar] [CrossRef]
- Orchard, P.J.; Markowski, T.W.; Higgins, L.A.; Raymond, G.V.; Nascene, D.R.; Miller, W.P.; Pierpont, E.I.; Lund, T.C. Association between APOE4 and biomarkers in cerebral adrenoleukodystrophy. Sci. Rep. 2019, 9, 7858. [Google Scholar] [CrossRef] [Green Version]
- Richmond, P.A.; van der Kloet, F.; Vaz, F.M.; Lin, D.; Uzozie, A.; Graham, E.; Kobor, M.; Mostafavi, S.; Moerland, P.D.; Lange, P.F.; et al. Multi-Omic Approach to Identify Phenotypic Modifiers Underlying Cerebral Demyelination in X-Linked Adrenoleukodystrophy. Front. Cell Dev. Biol. 2020, 8, 520. [Google Scholar] [CrossRef]
- Wang, H.; Davison, M.D.; Kramer, M.L.; Qiu, W.; Gladysheva, T.; Chiang, R.M.S.; Kayatekin, C.; Nascene, D.R.; Taghizadeh, L.A.; King, C.J.; et al. Evaluation of Neurofilament Light Chain as a Biomarker of Neurodegeneration in X-Linked Childhood Cerebral Adrenoleukodystrophy. Cells 2022, 11, 913. [Google Scholar] [CrossRef]
- Manek, R.; Zhang, Y.V.; Berthelette, P.; Hossain, M.; Cornell, C.S.; Gans, J.; Anarat-Cappillino, G.; Geller, S.; Jackson, R.; Yu, D.; et al. Blood phenylalanine reduction reverses gene expression changes observed in a mouse model of phenylketonuria. Sci. Rep. 2021, 11, 22886. [Google Scholar] [CrossRef]
- Capolongo, G.; Zacchia, M.; Perna, A.; Viggiano, D.; Capasso, G. Urinary proteome in inherited nephrolithiasis. Urolithiasis 2019, 47, 91–98. [Google Scholar] [CrossRef] [PubMed]
- Assimos, D.G. Re: Urine Proteomic Profiling in Patients with Nephrolithiasis and Cystinuria. J. Urol. 2019, 202, 25. [Google Scholar] [CrossRef] [PubMed]
- Bourderioux, M.; Nguyen-Khoa, T.; Chhuon, C.; Jeanson, L.; Tondelier, D.; Walczak, M.; Ollero, M.; Bekri, S.; Knebelmann, B.; Escudier, E.; et al. A new workflow for proteomic analysis of urinary exosomes and assessment in cystinuria patients. J. Proteome Res. 2015, 14, 567–577. [Google Scholar] [CrossRef] [PubMed]
- Kovacevic, L.; Lu, H.; Goldfarb, D.S.; Lakshmanan, Y.; Caruso, J.A. Urine proteomic analysis in cystinuric children with renal stones. J. Pediatr. Urol. 2015, 11, e217.e1–e217.e6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kovacevic, L.; Caruso, J.A.; Lu, H.; Kovacevic, N.; Lakshmanan, Y.; Carruthers, N.J.; Goldfarb, D.S. Urine proteomic profiling in patients with nephrolithiasis and cystinuria. Int. Urol. Nephrol. 2019, 51, 593–599. [Google Scholar] [CrossRef] [PubMed]
- Yang, F.; Guan, Y.; Feng, X.; Rolfs, A.; Schlüter, H.; Luo, J. Proteomics of the corpus callosum to identify novel factors involved in hypomyelinated Niemann-Pick Type C disease mice. Mol. Brain 2019, 12, 17. [Google Scholar] [CrossRef]
- Sutcliffe, D.J.; Dinasarapu, A.R.; Visser, J.E.; Hoed, J.D.; Seifar, F.; Joshi, P.; Ceballos-Picot, I.; Sardar, T.; Hess, E.J.; Sun, Y.V.; et al. Induced pluripotent stem cells from subjects with Lesch-Nyhan disease. Sci. Rep. 2021, 11, 8523. [Google Scholar] [CrossRef]
- Raimo, S.; Zura-Miller, G.; Fezelinia, H.; Spruce, L.A.; Zakopoulos, I.; Mohsen, A.W.; Vockley, J.; Ischiropoulos, H. Mitochondrial morphology, bioenergetics and proteomic responses in fatty acid oxidation disorders. Redox Biol. 2021, 41, 101923. [Google Scholar] [CrossRef]
- Edhager, A.V.; Stenbroen, V.; Nielsen, N.S.; Bross, P.; Olsen, R.K.J.; Gregersen, N.; Palmfeldt, J. Proteomic investigation of cultivated fibroblasts from patients with mitochondrial short-chain acyl-CoA dehydrogenase deficiency. Mol. Genet. Metab. 2014, 111, 360–368. [Google Scholar] [CrossRef]
- Cruz Guzmán, O.D.R.; Chávez García, A.L.; Rodríguez-Cruz, M. Muscular dystrophies at different ages: Metabolic and endocrine alterations. Int. J. Endocrinol. 2012, 2012, 485376. [Google Scholar] [CrossRef]
Disease | Disease Type | Altered Protein or Gene | Sample Type | Technique | Reference |
---|---|---|---|---|---|
Methyl malonic aciduria (MMA) | Methylmalonicacidemia | Methylmalonyl-CoA mutase (MUT) enzyme | HEK 293 cells mutated using CRISPR/Cas9 technique | Label-free LC-MS/MS | [60] |
Fabry disease [61,62,63] | Lysosomal storage disease | α-galactosidase A | Human urine samples | Label-free LC-MS/MS (discovery) SRM (validation) | [64] |
Human urine samples | Label-free LC-MS/MS (discovery) SRM (validation) | [65] | |||
Human plasma samples | iTRAQ labelling (discovery) SRM (validation) | [66] | |||
Human urine samples | MRM | [67] | |||
Gaucher disease | Lysosomal storage disease | Glucocerebrosidase | Human blood | iTRAQ labelling | [68] |
Mucopolysaccharidosis MPS I | Lysosomal storage disease | α-L-iduronidase | Mouse brain | Label-free LC-MS/MS | [69] |
Human urine samples | Label-free LC-MS/MS (discovery) SRM (validation) | [70] | |||
Dried blood spots (DBS) | OLINK Proseek Multiplex Inflammation | [71] | |||
Mucopolysaccharidosis MPS II | Lysosomal storage disease | Iduronatesulfatase | Human urine samples | Label-free LC-MS/MS (discovery) SRM (validation) | [70] |
Dried blood spots (DBS) and buccal swabs | Immunocapture and LC-MS/MS (Immuno-SRM) | [72] | |||
Human urine samples | Label-free LC-MS/MS (discovery) SRM (validation) | [70] | |||
Mucopolysaccharidosis MPS IIIB | Lysosomal storage disease | α-N-Acetylglucosaminidase | Mouse brain | LC-MS/MS | [73] |
Mucopolysaccharidosis MPIV A | Lysosomal storage disease | N-acetylgalactosamine-6-sulfate sulfatase (GALN) | Human urine samples | Label-free LC-MS/MS (discovery) SRM (validation) | [70] |
Primary fibroblast culture | Label-free LC-MS/MS SWATH-MS | [74] | |||
Human leukocytes | Label-free LC-MS/MS SWATH-MS | [75] | |||
Human plasma | Label-free LC-MS/MS SWATH-MS | [76] | |||
Adrenoleukodystrophy (X-ALD) | Peroxisomal disorder | Long-chain fatty acid accumulation in plasma and tissues | CSF samples | iTRAQ labelling | [77] |
Serum samples | Multi-omic approach | [78] | |||
CSF samples | OLINK Proximity Extension Assay | [79] | |||
Phenylketonuria (PKU) | Amino acid metabolism | Phenylalanine hydroxylase | Mouse liver samples | Label-free LC-MS/MS spectral count | [80] |
Cystinuria [81] | Inborn errors of metabolism | Variants in genes SLC3A1 (type I) SLC7A9 (type II and type III) | Human urine samples | LC-MS/MS TMT labelling | [82] |
Human exosomes urine samples | Label-free LC-MS/MS | [83] | |||
Human urine samples | Label-free LC-MS/MS spectral count | [84] | |||
Human urine samples | LC-MS/MS TMT labelling | [85] | |||
Niemann-Pick type C disease | Cholesterol metabolism | HE1 | Mouse corpus callosum | Label-free LC-MS/MS | [86] |
Lesch-Nyhandisease | Purine metabolism | Hypoxanthine-guanine phosphoribosyl transferase | Induced pluripotent stem cell (iPSC) lines from fibroblast | Label-free LC-MS/MS | [87] |
VLCAD deficiency disease | Fatty acid oxidation disorder | Variants in VLCAD | Human primary cell lines with VLCAD and TFP mutations | Label-free LC-MS/MS | [88] |
SCAD deficiency disease | Fatty acid oxidation disorder | Variants in SCAD | Primary fibroblasts culture | Label-free LC-MS/MS | [89] |
Duchenne muscular dystrophy (DMD) | Dystrophinopathies | Dystrophin | Human blood samples (plasma and serum) | Antibody suspension bead arrays | [36] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chantada-Vázquez, M.d.P.; Bravo, S.B.; Barbosa-Gouveia, S.; Alvarez, J.V.; Couce, M.L. Proteomics in Inherited Metabolic Disorders. Int. J. Mol. Sci. 2022, 23, 14744. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314744
Chantada-Vázquez MdP, Bravo SB, Barbosa-Gouveia S, Alvarez JV, Couce ML. Proteomics in Inherited Metabolic Disorders. International Journal of Molecular Sciences. 2022; 23(23):14744. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314744
Chicago/Turabian StyleChantada-Vázquez, Maria del Pilar, Susana B. Bravo, Sofía Barbosa-Gouveia, José V. Alvarez, and María L. Couce. 2022. "Proteomics in Inherited Metabolic Disorders" International Journal of Molecular Sciences 23, no. 23: 14744. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314744